Core Viewpoint - MicroPort Robotics-B (02252) has achieved a significant milestone with over 200 global commercial orders for its TiMeye® laparoscopic surgical robot, indicating widespread recognition of its clinical value and safety [1] Group 1: Company Performance - As of the announcement date, the company has completed nearly 130 installations of the TiMeye system, demonstrating its growing market presence [1] - The stock opened over 3% higher and is currently trading at 26.8 HKD with a transaction volume of 2.987 million HKD [1] Group 2: Product Development - The TiMeye system is the first remote surgical robot approved for commercial use, with approvals in nearly 10 countries including China, India, and Brazil, covering regions with nearly half of the global population [1] - The system has successfully completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate [1] Group 3: Market Recognition - The increase in commercial orders and installations reflects the system's systematic certification of safety, stability, and reliability, as recognized by surgeons from various countries and medical backgrounds [1]

Core Viewpoint - As of February 12, 2026, Yingke Medical (300677) closed at 40.08 yuan, down 2.6%, with a turnover rate of 1.46% and a trading volume of 68,000 hands, amounting to a transaction value of 274 million yuan [1] Group 1: Market Performance - On February 12, 2026, the net outflow of main funds was 25.52 million yuan, accounting for 9.31% of the total transaction value, while retail investors saw a net inflow of 31.69 million yuan, representing 11.56% of the total transaction value [1] - Over the past five days, the stock has experienced fluctuations in net fund flows, with notable outflows on February 9 and February 12, and a net inflow from retail investors on February 12 [2] Group 2: Financing and Margin Trading - On February 12, 2026, the financing buy-in was 19.75 million yuan, while the financing repayment was 28.53 million yuan, resulting in a net repayment of 8.78 million yuan [2] - The margin trading balance stood at 503 million yuan, with a short selling volume of 3,100 shares and a remaining short selling balance of 9.41 million yuan [3] Group 3: Company Financials and Industry Comparison - Yingke Medical's total market capitalization is 26.207 billion yuan, with a net asset value of 18.467 billion yuan and a net profit of 924 million yuan, ranking 8th, 4th, and 7th respectively in the medical device industry [5] - The company reported a year-on-year revenue increase of 4.6% to 7.425 billion yuan for the first three quarters of 2025, with a net profit increase of 34.47% to 924 million yuan [5] - The gross profit margin is 23.7%, which is significantly lower than the industry average of 51.01%, indicating potential areas for improvement [5]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in treating primary progressive multiple sclerosis (PPMS), marking a significant advancement in the treatment landscape [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with unmet needs in PPMS due to limited treatment options [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial for PPMS included 985 patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11][24]. - The safety profile of Fenebrutinib was comparable to Ocrelizumab, with a similar incidence of adverse events [22][24]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x [35][36]. - Specific segments like chemical pharmaceuticals and biological products have higher valuations, indicating investor confidence in these areas [35][36].

微创心通-B发布公告，股份合并将于2026年2月24日(星期二)起生效，并于上午九时正起开始买卖。股 份合并生效后及假设自公告日期直至股份合并生效日期概无发行或购回及注销额外现有股份，12.73亿 股合并股份将获发行并缴足。 香港联交所最新资料显示，2月12日，微创心通-B(02160)股东将股票由渣打银行(香港)转入高盛(亚洲)证 券，转仓市值4.24亿港元，占比8.53%。 ...

Core Viewpoint - The Jiangsu Medical Device Technology Industrial Park, Medpark, is experiencing significant growth and innovation, positioning itself as a key player in the high-end medical device industry, with a focus on research, production, and sales [1][10]. Group 1: Innovation and Development - The park has seen the signing of major projects, such as the headquarters of Shangmei Medical Group, which aims to create a comprehensive base for research, production, and sales [1]. - Numerous products from the park have been included in Jiangsu Province's innovative medical device catalog, showcasing the park's commitment to innovation [1]. - Companies like Suzhou Langmu Medical Technology are developing groundbreaking products, such as a micro-invasive glaucoma stent, which addresses a significant clinical need in China [2]. Group 2: Achievements and Recognition - The park has achieved notable milestones, including the establishment of national standards for wearable brain-machine interface products and the approval of various medical devices by the FDA [3][4]. - Medpark has been recognized with multiple awards, including being named a top 30 most vibrant biopharmaceutical industrial park in China [4]. Group 3: Support and Services - Medpark offers a comprehensive public service system, including high-level research institutions and a unique high-end medical device technology innovation center, which supports companies in their development processes [5][6]. - The park has implemented a "2+5+N" service system, providing tailored support for companies at various stages of development, including financial and legal services [8][9]. Group 4: Market Potential and Future Outlook - The medical device industry is characterized as a "sunrise industry," with significant growth potential driven by innovation and technological advancements [1][10]. - The park aims to accelerate its growth towards becoming a billion-level medical device industry base, leveraging its resources and services to support enterprise development [1][10].

Financial Data and Key Metrics Changes - For the full year 2025, total adjusted constant currency revenue growth was 13% and adjusted EBITDA growth was 26% year-over-year, resulting in positive free cash flow while investing in future growth [5][17] - Total adjusted revenues for Q4 2025 were $118.3 million, up 18.5% compared to Q4 2024, with adjusted EBITDA increasing approximately 29% from $17.6 million to $22.7 million [16][17] - Adjusted EBITDA margin was 19.2% in Q4 2025, an improvement of approximately 110 basis points over the prior year [17] Business Line Data and Key Metrics Changes - Stent graft revenues grew 36% on a constant currency basis in Q4 2025, driven by AMDS in the U.S. and strong international growth [6][20] - On-X revenues increased 24% year-over-year on a constant currency basis, supported by global market share gains and new U.S. market opportunities [7][8] - Tissue processing revenue increased 6% year-over-year, while BioGlue revenues were flat compared to the same period last year [8][20] Market Data and Key Metrics Changes - Revenues in Asia Pacific increased 32%, North America increased 18%, EMEA increased 17%, and Latin America increased 9% compared to Q4 2024 [21] - Gross margins were 63% in both 2025 and 2024, with the 2024 margin negatively impacted by an idle plant charge due to a cybersecurity incident [21] Company Strategy and Development Direction - The company plans to replicate its strategy by introducing additional stent graft products from Europe to the U.S. and Japan, aiming to expand its total addressable market [7] - Key growth drivers include AMDS commercialization in the U.S., On-X heart valve data, NEXUS PMA, and the ARTISAN IDE trial [33][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategies, anticipating continued double-digit revenue growth and EBITDA margin expansion [14][28] - The company expects constant currency growth between 10%-14% for the full year 2026, with specific growth rates for different product lines [25][27] Other Important Information - The company recorded a $2.3 million adjustment to revenue for estimated payback obligations due to Italian government legislation, which has been excluded from adjusted revenue [18][19] - Free cash flow for the full year was approximately $1 million, despite significant investments in the business [24] Q&A Session Summary Question: Impact of Italian clawback on growth - Management clarified that the Italian payback was specific to the EMEA line and did not impact major product lines [39] Question: Sell-in versus sell-through for AMDS - Management noted that implantations are continuing to grow and emphasized the importance of positive first experiences for surgeons [42] Question: Progress on AMDS target accounts - Management indicated that they are in the early stages of account openings and expect significant growth in 2026 [46] Question: Market opportunity for NEXUS - Management described the NEXUS market as nascent, with a U.S. market opportunity of $150 million, and expressed confidence in gaining market share [50] Question: Pricing for AMDS and NEXUS - Management affirmed that the pricing assumptions for AMDS and NEXUS remain appropriate due to favorable reimbursement conditions [56] Question: CapEx plans for 2026 - Management indicated that the increased CapEx is primarily for capacity expansion for On-X and internal IT investments [75]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Full year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [16] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, compared to $7.1 million, or 54.2% in Q4 2024 [14] - Net loss for Q4 2025 was $3.2 million, or a loss of $0.19 per share, compared to net income of $1.5 million, or $0.09 per diluted share in Q4 2024 [15] - Full year net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, with no sales to the largest customer [5][22] - Utilization across the Fair Deal Agreement program increased substantially, with treatments up more than eightfold year-over-year and the number of patients treated increasing by over 250% [6] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [7][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil clearance anticipated in 2026 [28] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technology is expected to enhance physician reimbursement and support broader adoption [4][20] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [8][19] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with greater clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on educating physicians about the new reimbursement codes to drive adoption and growth [5][8] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, unchanged from the previous year, and no outstanding debt [18] - Research and development expenses for 2025 increased to $7.8 million, primarily due to higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Guidance on revenue growth excluding the largest customer - Management confirmed that projections for 2026 do not include expectations from the largest customer, as they are reevaluating their model moving forward [22][23] Question: Update on TDI and FDA approval - Management indicated ongoing efforts with the FDA regarding TDI but could not provide a timeline for approval [25] Question: International demand outlook - Management highlighted strong demand in China and growth in Taiwan, with expectations for further expansion in Asia and South America [27][28] Question: Reaction to reimbursement and system mix - Management noted a shift towards outright purchases and leasing options due to improved reimbursement clarity, with a stronger focus on SRT technology [37][41] Question: Interest from private equity-backed groups - Increased interest from private equity groups was noted, with a reevaluation of acquisition strategies due to clearer reimbursement pathways [42]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a growth of 4% year-over-year, while full year revenue reached $56.7 million, reflecting a 10% increase [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the same quarter of the previous year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, an increase of 4%, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The ongoing BENEFIT-HF trial could potentially triple the addressable market to approximately $30 billion if successful [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, which is a significant milestone for the company [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around 3 active territories on a quarterly basis, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: Can you discuss the path to profitability? - The company has sufficient cash reserves and access to additional capital, with a focus on generating leverage through sales productivity [75]

Financial Data and Key Metrics Changes - For the full year of 2025, total adjusted constant currency revenue growth was 13% and Adjusted EBITDA growth was 26% year-over-year, resulting in positive free cash flow for the year [4][12] - Total adjusted revenues for Q4 2025 were $118.3 million, up 18.5% compared to Q4 2024, while adjusted EBITDA increased approximately 29% from $17.6 million to $22.7 million [12][13] - Adjusted EBITDA margin was 19.2% in Q4 2025, an improvement of approximately 110 basis points over the prior year [13] Business Line Data and Key Metrics Changes - Stent graft revenues grew 36% on a constant currency basis in Q4 2025 compared to the same period last year, driven by AMDS in the U.S. and strong international growth [5][16] - On-X revenues grew 24% year-over-year on a constant currency basis in Q4 2025, supported by global market share gains and new U.S. market opportunities [6][16] - Tissue processing revenue increased 6% year-over-year on a constant currency basis in Q4 2025, while BioGlue revenues were flat compared to the same period last year [7][16] Market Data and Key Metrics Changes - Revenues in Asia Pacific increased 32%, North America increased 18%, EMEA increased 17%, and Latin America increased 9% compared to Q4 2024 [17] - Gross margins were 63% in both 2025 and 2024, with the 2024 gross margin negatively impacted by an idle plant charge due to a cybersecurity incident [17] Company Strategy and Development Direction - The company aims to replicate its successful strategy by introducing additional stent graft products generating revenue in Europe to the U.S. and Japan, which is expected to expand the total addressable market [5] - Key growth drivers include the commercialization of AMDS in the U.S., leveraging new clinical data for On-X heart valves, and advancing the NEXUS PMA [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering sustainable double-digit revenue growth and driving EBITDA margin expansion, with expectations for constant currency growth between 10%-14% for 2026 [20][24] - The company anticipates challenges in the AMDS launch due to tougher year-over-year comparisons but remains optimistic about growth opportunities [22][41] Other Important Information - The company recorded a $2.3 million adjustment to revenue for estimated payback obligations due to Italian government legislation, which has been excluded from adjusted revenue [14][15] - Free cash flow for the full year was approximately $1 million, despite significant investments in business expansion [19] Q&A Session Summary Question: Impact of Italian clawback on growth - Management clarified that the Italian payback impacted the EMEA line and did not skew the growth rates of major product lines [32][34] Question: Sell-in versus sell-through for AMDS - Management indicated that while specific revenue details are not disclosed, implantations are growing well, and the first experiences for surgeons have been positive [36][41] Question: Market opportunity for NEXUS - Management described the NEXUS market as nascent, with a U.S. market opportunity of $150 million, and emphasized the unique technology's potential to gain market share [42][44] Question: Pricing strategy for AMDS and NEXUS - Management confirmed that the pricing levels for AMDS and NEXUS are seen as appropriate, with favorable reimbursement dynamics supporting demand [51] Question: CapEx plans for 2026 - Management indicated that the $50 million CapEx for 2026 is primarily for capacity expansion for On-X and internal IT investments [68]

Core Viewpoint - The breast cancer NGS companion diagnostic kit developed by the company has entered the priority review channel of the National Medical Products Administration (NMPA), which will shorten the approval cycle for the product in China [1]. Product Development Progress - The entry of the diagnostic kit into the priority review channel is a significant technological advancement worth noting [2].